1-(4-(6,7-Dimethoxyquinazolin-4-yloxy)phenyl)-3-(4-(trifluoromethyl)phenyl)urea | 1292280-81-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(4-(6,7-Dimethoxyquinazolin-4-yloxy)phenyl)-3-(4-(trifluoromethyl)phenyl)urea
• 英文别名: 1-[4-(6,7-dimethoxyquinazolin-4-yl)oxyphenyl]-3-[4-(trifluoromethyl)phenyl]urea
• CAS: 1292280-81-9
• 化学式: C₂₄H₁₉F₃N₄O₄
• 分子量: 484.434
• InChiKey: LNQQJYGYCYVBCR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  35
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  94.6
• 氢给体数：
  2
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  4-氯-6,7-二甲氧基喹唑啉 在 四丁基溴化铵 、 三乙胺 、 sodium hydroxide 作用下， 以 氯仿 、 水 、 丁酮 为溶剂， 生成 1-(4-(6,7-Dimethoxyquinazolin-4-yloxy)phenyl)-3-(4-(trifluoromethyl)phenyl)urea
  参考文献：
  名称：

  Impact of aryloxy-linked quinazolines: A novel series of selective VEGFR-2 receptor tyrosine kinase inhibitors

  摘要：

  Three series of 6,7-dimethoxyquinazoline derivatives substituted in the 4-position by aniline, N-methylaniline and aryloxy entities, targeting EGFR and VEGFR-2 tyrosine kinases, were designed and synthesized. Pharmacological activities of these compounds have been evaluated for their enzymatic inhibition of VEGFR-2 and EGFR and for their antiproliferative activities on various cancer cell lines. We have studied the impact of the variation in the 4-position substitution of the quinazoline core. Substitution by aryloxy groups led to new compounds which are selective inhibitors of VEGFR-2 enzyme with IC50 values in the nanomolar range in vitro. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.01.137

文献信息

• Impact of aryloxy-linked quinazolines: A novel series of selective VEGFR-2 receptor tyrosine kinase inhibitors
  作者：Antonio Garofalo、Laurence Goossens、Perrine Six、Amélie Lemoine、Séverine Ravez、Amaury Farce、Patrick Depreux

  DOI：10.1016/j.bmcl.2011.01.137

  日期：2011.4

  Three series of 6,7-dimethoxyquinazoline derivatives substituted in the 4-position by aniline, N-methylaniline and aryloxy entities, targeting EGFR and VEGFR-2 tyrosine kinases, were designed and synthesized. Pharmacological activities of these compounds have been evaluated for their enzymatic inhibition of VEGFR-2 and EGFR and for their antiproliferative activities on various cancer cell lines. We have studied the impact of the variation in the 4-position substitution of the quinazoline core. Substitution by aryloxy groups led to new compounds which are selective inhibitors of VEGFR-2 enzyme with IC50 values in the nanomolar range in vitro. (C) 2011 Elsevier Ltd. All rights reserved.